IASLC Releases Immunotherapy Atlas
Posted: Wednesday, May 24, 2017
At the recent European Lung Cancer Conference (ELCC), the International Association for the Study of Lung Cancer (IASLC) released its Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, reportedly the first publication to collectively focus on all five programmed cell death ligand 1 (PD-L1) immunohistochemistry assays.
With much confusion surrounding which assay to use for PD-L1 testing and whether the assays are interchangeable, an expert panel of authors created this resource for physicians and others involved in lung cancer diagnosis and treatment to highlight areas of clarity and debate. Also, the editors hope this text eventually may also provide patients with a more comprehensive understanding of immunotherapy for lung cancer.
Among the chapters in this Atlas are “Cancer Immunotherapy for Lung Cancer,” “Immunohistochemistry for PD-L1,” “Other Anti–PD-L1 Clones: Alternative Assays and Laboratory-Developed Tests,” and “Implementation of PD-L1 Testing for Personalized Therapy for Lung Cancer.” Given the rapidly evolving nature of this field and the ongoing investigation of other biomarkers related to the immune response, the authors noted that updates to this Atlas clearly will be needed.